Homology Medicines announced that Julie Jordan, M.D., has been promoted to Chief Medical Officer, CMO. Previously, Dr. Jordan held the role of Senior Vice President, Head of Clinical Development and Operations, at Homology, and she has been instrumental in advancing Homology’s gene editing and gene therapy clinical programs.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FIXX:
- Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
- Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
- Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
- Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting
